Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EHTH
EHTH logo

EHTH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy eHealth Inc (EHTH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.650
1 Day change
52 Week Range
5.890
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

eHealth Inc (EHTH) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows no significant positive momentum, lacks strong trading signals, and has limited catalysts for growth. It would be prudent to monitor the stock for better entry points or more favorable conditions.

Technical Analysis

The stock is trading below its pivot level (1.706) with key support at 1.595. RSI is neutral at 44.792, and MACD is above zero but positively contracting, indicating no strong trend. Moving averages are converging, suggesting indecision in price movement.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
2

Positive Catalysts

  • NULL. No recent news or significant positive developments identified.

Neutral/Negative Catalysts

  • Hedge funds are heavily selling, with a 1442.15% increase in selling over the last quarter. Analysts maintain a Hold rating with a modest price target increase to $3, which is still below significant growth expectations.

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Deutsche Bank analyst raised the price target from $2 to $3 but maintained a Hold rating, reflecting limited confidence in the stock's near-term upside.

Wall Street analysts forecast EHTH stock price to rise
4 Analyst Rating
Wall Street analysts forecast EHTH stock price to rise
1 Buy
3 Hold
0 Sell
Hold
Current: 1.650
sliders
Low
8
Averages
9.67
High
12
Current: 1.650
sliders
Low
8
Averages
9.67
High
12
Deutsche Bank
George Hill
Hold
maintain
$2 -> $3
AI Analysis
2026-05-08
Reason
Deutsche Bank
George Hill
Price Target
$2 -> $3
AI Analysis
2026-05-08
maintain
Hold
Reason
Deutsche Bank analyst George Hill raised the firm's price target on eHealth to $3 from $2 and keeps a Hold rating on the shares.
RBC Capital
Sector Perform
downgrade
$9 -> $3
2026-03-11
Reason
RBC Capital
Price Target
$9 -> $3
2026-03-11
downgrade
Sector Perform
Reason
RBC Capital lowered the firm's price target on eHealth to $3 from $9 and keeps a Sector Perform rating on the shares. The company's strong Q4 results were overshadowed by a softer-than-expected 2026 guide, with revenue coming in significantly below expectations, the analyst tells investors in a research note. The soft guidance is related to the pullback in marketing spend of a major Medicare Advantage payor as well as conservative assumptions around next year's annual enrollment period, RBC adds.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EHTH
Unlock Now

People Also Watch